XOMAP XOMA Corporation
USHealthcareAs of 2026-07-10 16:00
Why XOMAP matters now
XOMA Corporation (XOMAP) is a US stock in Healthcare. The latest InvestLog snapshot shows $24.97 with -0.04% on the session and $301.2M in market capitalization; recent performance reads 1-month +0.57% and YTD -5.31%.
The latest financial table shown here is Q1 2026, with revenue of $12.3M, net income of $4.5M, and EPS of $0.17. Investors can compare that operating picture with valuation signals such as P/E 21.09 and FCF yield 1.3%.
Valuation
P/E (TTM)
21.09
PEG
0.03
P/B
4.41
P/S
14.50
EV/EBITDA
11.08
DCF Value
$-50.41
FCF Yield
1.3%
Div Yield
0.0%
Margins & Returns
Gross Margin
93.3%
Operating Margin
13.7%
Net Margin
87.0%
ROE
30.2%
ROA
11.6%
ROIC
1.9%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $12.3M | $4.5M | $0.17 |
| Q4 2025 | $1.4M | $6.1M | $0.26 |
| FY 2025 | $52.1M | $31.7M | $1.46 |
| Q3 2025 | $532.0K | $14.1M | $0.70 |
Related Stocks
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
0.87
XOMA Corporation specializes in aggregating biotechnology royalties, operating globally across Europe, the United States, and the Asia Pacific. The company acquires future economic rights, such as royalties and milestone payments, linked to therapeutic candidates still in pre-commercial development that have been licensed to pharmaceutical or biotechnology companies. Its primary focus is on early to mid-stage clinical assets, typically in Phase 1 and 2, which hold significant commercial potential and are partnered with other firms. XOMA currently manages a diverse portfolio of approximately 70 assets. Founded in 1981, the corporation maintains its headquarters in Emeryville, California.